Karki Radha, Park Chanmi, Jun Kyu-Yeon, Kadayat Tara Man, Lee Eung-Seok, Kwon Youngjoo
College of Pharmacy, Yeungnam University, Gyeongsan 712-749, Republic of Korea.
College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Global Top 5 Program Ewha Womans University, Seoul 120-750, Republic of Korea.
Eur J Med Chem. 2015 Jan 27;90:360-78. doi: 10.1016/j.ejmech.2014.11.045. Epub 2014 Nov 24.
Dihydroxylated 2,4-diphenyl-6-aryl pyridine derivatives were simply achieved using Claisen-Schmidt condensation reaction and modified Kröhnke pyridine synthetic method. Total forty-five compounds were designed and synthesized which contain hydroxyl groups at ortho, meta or para position of 2- and 4-phenyl rings attached to the central pyridine. They were evaluated for topoisomerase I and II inhibitory activity, and cytotoxicity against several human cancer cell lines for the development of novel antitumor agents. Most of the prepared compounds exhibited significant antiproliferative activity on human cancer cell lines, HCT15 and K562, as well as potent topo II inhibitory activity comparable to or stronger than etoposide. The structure-activity relationship demonstrated that compounds with hydroxyl group at meta or para position of 2-phenyl ring in combination with hydroxyl at ortho, meta or para position of 4-phenyl ring displayed the most potent topoisomerase II inhibitory activity and cytotoxicity. Positive correlation between topoisomerase II inhibition and cytotoxicity was obtained for several compounds (30, 35, 36, 40-45, 49, 54, 56). Compound 56 showed the most potent topoisomerase II inhibitory activity at low concentration and functioned as a topoisomerase poison like the mode of action of etoposide.
利用克莱森-施密特缩合反应和改良的克伦克吡啶合成方法,可简便地制得二羟基化的2,4-二苯基-6-芳基吡啶衍生物。共设计并合成了45种化合物,这些化合物在连接于中心吡啶的2-苯基环和4-苯基环的邻位、间位或对位含有羟基。对它们进行了拓扑异构酶I和II抑制活性以及对几种人类癌细胞系的细胞毒性评估,以开发新型抗肿瘤药物。大多数制备的化合物对人类癌细胞系HCT15和K562表现出显著的抗增殖活性,以及与依托泊苷相当或更强的拓扑异构酶II抑制活性。构效关系表明,2-苯基环间位或对位带有羟基且4-苯基环邻位、间位或对位带有羟基的化合物表现出最强的拓扑异构酶II抑制活性和细胞毒性。几种化合物(30、35、36、40 - 45、49、54、56)的拓扑异构酶II抑制作用与细胞毒性之间存在正相关。化合物56在低浓度下表现出最强的拓扑异构酶II抑制活性,并且像依托泊苷的作用模式一样作为一种拓扑异构酶毒物发挥作用。